Erratum: Patient Perceptions of Switching to a Generic Dry Powder Inhaler - Increased Understanding Through Journey Mapping [Corrigendum]. [PDF]
Int J Chron Obstruct Pulmon Dis, 2022 europepmc +1 more source
Development of Novel Fluticasone/Salmeterol/Tiotropium-Loaded Dry Powder Inhaler and Bioequivalence Assessment to Commercial Products in Rats. [PDF]
PharmaceuticsCho H, Lee H, Hwang D.
europepmc +1 more source
Demystifying Dry Powder Inhaler Resistance with Relevance to Optimal Patient Care. [PDF]
Clin Drug InvestigCapstick TGD +4 more
europepmc +1 more source
Dry powder inhaler design and particle technology in enhancing Pulmonary drug deposition: challenges and future strategies. [PDF]
DaruIslam N, Suwandecha T, Srichana T.
europepmc +1 more source
Dry Powder Inhaler Formulation of Lactobacillus rhamnosus GG Targeting Pseudomonas aeruginosa Infection in Bronchiectasis Maintenance Therapy. [PDF]
PharmaceuticsTran TT +4 more
europepmc +1 more source
Inhaler personalisation based on peak inspiratory flow (PIF) among dry powder inhaler users: a pilot randomised control trial (RCT) in COPD. [PDF]
J Pharm Policy PractJailaini MFM +4 more
europepmc +1 more source
Patient considerations in the treatment of COPD: Focus on the new combination inhaler fluticasone furoate/umeclidinium/vilanterol [PDF]
, 2018 Calabrese, Giovanna +2 more
core +1 more source
Implementation of a Metered-Dose Inhaler to Dry-Powder Inhaler National Formulary Transition.
JAMA Netw OpenRabin AS +6 more
europepmc +1 more source
A Novel Combined Dry Powder Inhaler Comprising Nanosized Ketoprofen-Embedded Mannitol-Coated Microparticles for Pulmonary Inflammations: Development, In Vitro-In Silico Characterization, and Cell Line Evaluation. [PDF]
Pharmaceuticals (Basel)Banat H +5 more
europepmc +1 more source